Biopharmaceutical Company Announces $2M Non-Dilutive Financing
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has recently announced a amendment to its March 2022 ex-US royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. (R-Bridge). This development represents a noteworthy milestone for the company, encompassing both financial gains and adjustments aimed at bolstering its position in the biopharmaceutical landscape. $Trevena(TRVN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
